


Amendments to the Claims:

This listing of claims will replace the current set of claims in the application:

Listing of Claims:

Claim 1 (currently amended): A compound of Formula I



or a pharmaceutically acceptable salt or stereoisomer thereof, wherein

A and B are independently N or $N^+—O^-$;

Y is O, S or $N-R^4$;

R^1 and R^2 are independently:

- 1) H,
- 2) $O_r(C_1-C_6)$ perfluoroalkyl,
- 3) OH,
- 4) CN,
- 5) halogen,
- 6) $(C=O)_rO_s(C_1-C_{10})$ alkyl,
- 7) $(C=O)_rO_s(C_2-C_{10})$ alkenyl,
- 8) $(C=O)_rO_s(C_2-C_{10})$ alkynyl,
- 9) $(C=O)_rO_s$ aryl,
- 10) $(C=O)_rO_s$ heterocyclyl,

11) $(C_0-C_6)\text{alkyl}-NR^aR^b$, or

12) $(C_1-C_6)\text{heterocyclyl}$,

wherein r and s are independently 0 or 1, and said alkyl, alkenyl, alkynyl, aryl, and heterocyclyl is optionally substituted with one or more substituents selected from R^7 ;

R^4 is H, aryl or $(C_1-C_6)\text{alkyl}$;

R^5 is:

- 1) H,
- 2) SO_2R^c ,
- 3) $(C=O)_rR^c$, wherein r is 0 or 1, or
- 4) CO_2R^c ;

R^6 is:

- 1) phenyl,
- 2) CN,
- 3) halogen,
- 4)
- 5)
- 6)
- 7) or
- 8) 4) heterocyclyl,

wherein said phenyl and heterocyclyl are optionally substituted with one or more substituents selected from R^7 ;

R^7 is:

- 1) $O_r(C=O)_sNR^aR^b$,
- 2) $(C=O)_rO_s\text{aryl}$,

- 3) $(\text{C}=\text{O})_r\text{O}_s\text{-heterocyclyl}$,
- 4) halogen,
- 5) OH,
- 6) oxo,
- 7) $\text{O}(\text{C}_1\text{-C}_3)\text{perfluoroalkyl}$,
- 8) $(\text{C}_1\text{-C}_3)\text{perfluoroalkyl}$,
- 9) $(\text{C}=\text{O})_r\text{O}_s(\text{C}_1\text{-C}_6)\text{alkyl}$,
- 10) CHO,
- 11) CO_2H ,
- 12) CN,
- 13) $(\text{C}_1\text{-C}_6)\text{alkyl-NR}^a\text{R}^b$, or
- 14) $(\text{C}_1\text{-C}_6)\text{alkyl-heterocyclyl}$,

wherein r and s are independently 0 or 1, and said aryl, heterocyclyl and alkyl are optionally substituted with one to three substituents selected from R^d ;

R^a and R^b are taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 5-7 members in each ring and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said monocyclic or bicyclic heterocycle optionally substituted with one or more substituents selected from R^d ;

R^c is $(\text{C}_1\text{-C}_6)\text{alkyl}$, aryl, or heterocyclyl; and

R^d is:

- 1) $(\text{C}=\text{O})_r\text{O}_s(\text{C}_1\text{-C}_{10})\text{alkyl}$, wherein r and s are independently 0 or 1, optionally substituted with up to three substituents selected from OH, $(\text{C}_1\text{-C}_6)\text{alkoxy}$, halogen, heterocyclyl, CN, oxo, $\text{N}(\text{R}^e)_2$ and $\text{S}(\text{O})_2\text{R}^c$,
- 2) $\text{O}_r(\text{C}_1\text{-C}_3)\text{perfluoroalkyl}$,
- 3) $(\text{C}_0\text{-C}_6)\text{alkylene-S}(\text{O})_m\text{R}^c$, wherein m is 0, 1, or 2,

- 4) oxo,
- 5) OH,
- 6) halo,
- 7) CN,
- 8) (C₀-C₆)alkylene-aryl, optionally substituted with up to three substituents selected from R^e,
- 9) (C₀-C₆)alkylene-heterocyclyl, optionally substituted with up to three substituents selected from R^e,
- 10) C(O)R^c,
- 11) CO₂R^c,
- 12) C(O)H,
- 13) N(R^e)₂, or
- 14) CO₂H;

R^e is:

- 1) H,
- 2) (C₁-C₆)alkyl, optionally substituted with one or more substituents selected from OH, heterocyclyl, (C₁-C₆)alkoxy, halogen, CN, oxo, N(R^f)₂ and S(O)₂R^c,
- 3) aryl, optionally substituted with one or more substituents selected from OH, heterocyclyl, (C₁-C₆)alkoxy, halogen, CN, N(R^f)₂ and S(O)₂R^c,
- 4) heterocyclyl, optionally substituted with one or more substituents selected from OH, heterocyclyl, (C₁-C₆)alkoxy, halogen, CN, oxo, N(R^f)₂ and S(O)₂R^c, or
- 6) S(O)₂R^c, or

if two R^e's are on a nitrogen atom, they can be taken together with the nitrogen to form a heterocycle with 5-7 atoms, optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said heterocycle option-

ally substituted with one or more substituents selected from OH, (C₁-C₆)alkoxy, halogen, CN, oxo, N(R^f)₂ and S(O)₂R^c; and

R^f is H, aryl or (C₁-C₆)alkyl.

Claim 2 (currently amended): The compound of Claim 1, wherein

Y is S;

R¹ is H, (C₁-C₆)alkyl, or O(C₁-C₆)alkyl;

R² is:

- 1) H, provided that both R¹ and R² are not H at the same time,
- 2) O_r(C₁-C₆)perfluoroalkyl,
- 3) OH,
- 4) CN,
- 5) halogen,
- 6) (C=O)_rO_s(C₁-C₁₀)alkyl,
- 7) (C=O)_rO_s(C₂-C₁₀)alkenyl,
- 8) (C=O)_rO_s(C₂-C₁₀)alkynyl,
- 9) (C=O)_rO_saryl,
- 10) (C=O)_rO_sheterocyclyl,
- 11) (C₀-C₆)alkyl-NR^aR^b, or
- 12) (C₁-C₆)heterocyclyl,

wherein r and s are independently 0 or 1, and said alkyl, alkenyl, alkynyl, aryl, and heterocyclyl is optionally substituted with one or more substituents selected from R⁷;

R⁶ is:

- 1) phenyl,
- 2) CN,
- 3) halogen,
- 4)
- 5)
- 6)
- 7) — or
- 8) 4) heterocyclyl,

wherein said phenyl and heterocyclyl are optionally substituted with one to three substituents selected from R⁷;

R⁷ is:

- 1) O_r(C=O)_sNR^aR^b,
- 2) (C=O)_rO_saryl,
- 3) (C=O)_rO_s-heterocyclyl,
- 4) halogen,
- 5) OH,
- 6) oxo,
- 7) O(C₁-C₃)perfluoroalkyl,
- 8) (C₁-C₃)perfluoroalkyl,
- 9) (C=O)_rO_s(C₁-C₆)alkyl,
- 10) CHO,
- 11) CO₂H,
- 12) CN,
- 13) (C₁-C₆)alkyl-NR^aR^b, or
- 14) (C₁-C₆)alkyl-heterocyclyl,

wherein r and s are independently 0 or 1, and said aryl, heterocyclyl and alkyl are optionally substituted with one to three substituents selected from R^d;

R^a and R^b are taken together with the nitrogen to which they are attached to form a monocyclic 5-7 membered heterocycle optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said heterocycle optionally substituted with one to three substituents selected from R^d ; and

R^d is:

- 1) $(C=O)_rO_s(C_1-C_6)alkyl$, wherein r and s are independently 0 or 1, optionally substituted with up to three substituents selected from OH, $(C_1-C_6)alkoxy$, halogen, CN, oxo, $N(R^e)_2$ and $S(O)_2R^c$,
- 2) $O_r(C_1-C_3)perfluoroalkyl$,
- 3) $(C_0-C_6)alkylene-S(O)_mR^c$, wherein m is 0, 1, or 2,
- 4) oxo,
- 5) OH,
- 6) halo,
- 7) CN,
- 8) $(C_0-C_6)alkylene-aryl$, optionally substituted with up to three substituents selected from R^e ,
- 9) $(C_0-C_6)alkylene-heterocyclyl$, optionally substituted with up to three substituents selected from R^e ,
- 10) $(C_0-C_6)alkylene-N(R^e)_2$,
- 11) $C(O)R^c$,
- 12) CO_2R^c ,
- 13) $C(O)H$, or
- 14) CO_2H .

Claim 3 (currently amended): The compound of Claim 2, wherein A and B are N; and R⁶ is phenyl, halogen, CN, or pyridyl, said phenyl and pyridyl are optionally substituted with one to three substituents ~~selected~~ selected from R⁷.

Claim 4 (currently amended): The compound of Claim 3 wherein R¹ is H and R² is O_{FS}(C₁-C₆)alkyl, wherein FS is 0 or 1, optionally substituted with one to three substituents selected from R⁷, or (C₀-C₆)alkyl-NR^aR^b.

Claim 5 (original): A compound selected from:

2-({6-[4-(2-morpholin-4-ylethyl)piperazin-1-yl]pyrimidin-4-yl}amino)-1,3-thiazole-5-carbonitrile;

2-({6-[4-(2-morpholin-4-yl-2-oxoethyl)piperazin-1-yl]pyrimidin-4-yl}amino)-1,3-thiazole-5-carbonitrile;

N-(*tert*-butyl)-2-(4-{6-[(5-cyano-1,3-thiazol-2-yl)amino]pyrimidin-4-yl}piperazin-1-yl)acetamide;


2-({6-[4-(1,1-dioxidotetrahydrothien-3-yl)piperazin-1-yl]pyrimidin-4-yl}amino)-1,3-thiazole-5-carbonitrile;

2-(4-{6-[(5-cyano-1,3-thiazol-2-yl)amino]pyrimidin-4-yl}piperazin-1-yl)-*N*-isopropylacetamide;

2-(1-{6-[(5-cyano-1,3-thiazol-2-yl)amino]pyrimidin-4-yl}piperidin-4-yl)-*N*-isopropylacetamide;
and


2-({6-[4-(2-oxopiperidin-3-yl)piperazin-1-yl]pyrimidin-4-yl}amino)-1,3-thiazole-5-carbonitrile;
or a pharmaceutically acceptable salt or stereoisomer thereof.

Claim 6 (original): A compound which is 2-({6-[4-(1,1-dioxidotetrahydrothien-3-yl)piperazin-1-yl]pyrimidin-4-yl}amino)-1,3-thiazole-5-carbonitrile



or a pharmaceutically acceptable salt or stereoisomer thereof.


Claim 7 (original): A compound which is *N*-(*tert*-butyl)-2-(4-{6-[(5-cyano-1,3-thiazol-2-yl)amino]pyrimidin-4-yl}piperazin-1-yl)acetamide



or a pharmaceutically acceptable salt thereof.

Claim 8 (original): A compound which is the (R) or (S) enantiomer of 2-({6-[4-(1,1-dioxidotetrahydrothien-3-yl)piperazin-1-yl]pyrimidin-4-yl}amino)-1,3-thiazole-5-carbonitrile in enantiomerically pure form as characterized by an enatiomeric excess of at least 98%, or a pharmaceutically acceptable salt thereof.

Claim 9 (original): A compound which is 2-(4-{6-[(5-cyano-1,3-thiazol-2-yl)amino]pyrimidin-4-yl}piperazin-1-yl)-N-isopropylacetamide



or a pharmaceutically acceptable salt thereof.

Claim 10 (original): A pharmaceutical composition which is comprised of a compound in accordance with Claim 1 and a pharmaceutically acceptable carrier.

Claim 11 (canceled)

Claim 12 (previously amended): A method of treating cancer in a mammal in need of such treatment which is comprised of administering to said mammal a therapeutically effective amount of a compound of Claim 1, wherein said cancer is selected from cancers of the brain, genitourinary tract, lymphatic system, stomach, larynx and lung.

Claim 13 (previously amended): A method of treating cancer in a mammal in need of such treatment which is comprised of administering to said mammal a therapeutically effective amount of a compound of Claim 1, wherein said cancer is selected from histiocytic lymphoma, lung adenocarcinoma, small cell lung cancers, pancreatic cancer, glioblastomas and breast carcinoma.

Claim 14 (previously amended): A method of treating cancer in a mammal in need of such treatment which is comprised of administering to said mammal a therapeutically effective amount of a compound of Claim 1, wherein said cancer is selected from colorectal cancer, prostate cancer, breast cancer, and lung cancer.

Claim 15 (previously amended): A method of treating a disease in which angiogenesis is implicated, said disease is an ocular disease, which is comprised of administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Claim 1.

Claim 16 (canceled)

Claim 17 (previously amended): A method of treating retinal vascularization which is comprised of administering to a mammal in need of such treatment a therapeutically effective amount of compound of Claim 1.

Claim 18 (previously amended): A method of treating diabetic retinopathy which is comprised of administering to a mammal in need of such treatment a therapeutically effective amount of compound of Claim 1.

Claim 19 (canceled)

Claim 20 (original): The method of Claim 15 further comprising the use of photodynamic therapy with a photosensitive drug.

Claim 21 (original): The method of Claim 20 wherein the photosensitive drug is verteporfin.

Claim 22 (canceled)

Claim 23 (previously amended): A method of treating inflammatory diseases said diseases selected from rheumatoid arthritis, psoriasis, contact dermatitis and delayed hypersensitivity reactions, which comprises administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Claim 1.

Claims 24-25 (canceled)

Claim 26 (original): A pharmaceutical composition made by combining the compound of Claim 1 and a pharmaceutically acceptable carrier.

Claim 27 (original): A process for making a pharmaceutical composition which comprises combining a compound of Claim 1 with a pharmaceutically acceptable carrier.

Claim 28 (previously amended): A method of treating bone associated pathologies selected from osteosarcoma, osteoarthritis, and rickets which comprises administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Claim 1.

Claim 29 (original): The composition of Claim 10 further comprising a second compound selected from:

- 1) an estrogen receptor modulator,
- 2) an androgen receptor modulator,

- 3) retinoid receptor modulator,
- 4) a cytotoxic agent,
- 5) an antiproliferative agent,
- 6) a prenyl-protein transferase inhibitor,
- 7) an HMG-CoA reductase inhibitor,
- 8) an HIV protease inhibitor,
- 9) a reverse transcriptase inhibitor,
- 10) another angiogenesis inhibitor, and
- 11) a PPAR- γ agonist.

Claim 30 (original): The composition of Claim 29, wherein the second compound is another angiogenesis inhibitor selected from the group consisting of a tyrosine kinase inhibitor, an inhibitor of epidermal-derived growth factor, an inhibitor of fibroblast-derived growth factor, an inhibitor of platelet derived growth factor, an MMP inhibitor, an integrin blocker, interferon- α , interleukin-12, pentosan polysulfate, a cyclooxygenase inhibitor, carboxyamidotriazole, combretastatin A-4, squalamine, 6-O-(chloroacetyl-carbonyl)-fumagillol, thalidomide, angiostatin, troponin-1, and an antibody to VEGF.

Claim 31 (original): The composition of Claim 29, wherein the second compound is an estrogen receptor modulator selected from tamoxifen and raloxifene.

Claim 32 (original): The composition of Claim 10 further comprising a steroidal anti-inflammatory compound.

Claim 33 (original): The composition of Claim 10 further comprising an anti-hypertensive compound.

Claims 34-39 (canceled)

Claim 40 (previously amended): A method of reducing tissue damage following a cerebral ischemic event which comprises administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Claim 1.

Claims 41-42 (canceled)

Claim 43 (canceled)

Claim 44 (previously amended): A method to treat endometrioses which comprises administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Claim 1.

Claim 45 (previously amended): A method of treating diabetic retinopathy which comprises administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Claim 1 in combination with a PPAR- γ agonist.

Claim 46 (previously amended): A method of treating acute myeloid leukemia which comprises administering a therapeutically effective amount of a compound of Claim 1.

Claim 47 (canceled)